Glaukos Stock-Based Compensation 2014-2025 | GKOS

Glaukos stock-based compensation for the twelve months ending March 31, 2025 was $0.123B, a 16.41% increase year-over-year.

  • Glaukos annual stock-based compensation for 2024 was $0.05B, a 15.34% increase from 2023.
  • Glaukos annual stock-based compensation for 2023 was $0.044B, a 12.88% increase from 2022.
  • Glaukos annual stock-based compensation for 2022 was $0.039B, a 27.91% increase from 2021.

Glaukos Stock-Based Compensation 2014-2025 | GKOS

  • Glaukos annual stock-based compensation for 2024 was $0.05B, a 15.34% increase from 2023.
  • Glaukos annual stock-based compensation for 2023 was $0.044B, a 12.88% increase from 2022.
  • Glaukos annual stock-based compensation for 2022 was $0.039B, a 27.91% increase from 2021.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$183.6B
Thermo Fisher Scientific (TMO)$157.8B
Edwards Lifesciences (EW)$45.1B
Alcon (ALC)$42.4B
IDEXX Laboratories (IDXX)$42.4B
DexCom (DXCM)$33.2B
IQVIA Holdings (IQV)$27.3B
Mettler-Toledo (MTD)$24.3B
STERIS (STE)$22.5B
Waters (WAT)$17.2B
SONOVA HOLDING (SONVY)$17.1B
Hologic (HOLX)$14.1B
Sysmex ADR (SSMXY)$10.4B
Penumbra (PEN)$9.2B
Masimo (MASI)$8.7B
Globus Medical (GMED)$7.6B
Teleflex (TFX)$5B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3.9B
PROCEPT BioRobotics (PRCT)$3.2B
LivaNova (LIVN)$2.4B
Nihon Kohden (NHNKY)$2B
Veracyte (VCYT)$2B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.6B
Artivion (AORT)$1.3B
Paragon 28 (FNA)$1.1B
OPKO Health (OPK)$1.1B
Pulse Biosciences (PLSE)$1B
Tandem Diabetes Care (TNDM)$1B